Trial
NCT02312206
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Prothena Biosciences Ltd.
Collaborators
—
Condition
Primary Systemic (AL) Amyloidosis
Intervention
NEOD001
Why stopped
The VITAL study was terminated due to futility analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-14